P
Predictive Oncology
A leader in functional precision medicine harnessing the power of tumor to personalize therapy
About Predictive Oncology
Helomics operates in the precision medicine and AI-driven drug discovery market, focusing on personalized cancer treatment. The company serves oncologists and pharmaceutical companies by providing a unique technology that combines clinically validated primary tumor cell assays and drug response data from over 150,000 tumors with artificial intelligence. This allows for the testing of potential drugs against patient tumor cells much earlier in the drug discovery process, significantly improving the success rate of translating compounds into clinical use. Helomics' functional tumor profiling platform conducts genomic and functional tests on living tumors to determine drug responses, comparing the results with an extensive knowledge base to generate personalized treatment roadmaps for oncologists. The business model revolves around offering these advanced testing and profiling services, generating revenue through service fees from healthcare providers and partnerships with pharmaceutical companies.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2002
- Headquarters
- Pittsburgh, United States
- Employees
- 63
- Open positions
- None listed
- Dealroom signal
- 70.8/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, Biomarkers, Precision Medicine, Biotech and Pharma, AI Drug Discovery, Techbio, CompBio, Hard Tech
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| GROWTH EQUITY VCOther financing | Dec 2017 | $0 | — | Skyline Medical Inc. | — |
| SERIES EOther financing | Nov 2014 | $60M | $240M | HealthCare Royalty | — |
Growth signals
Latest recorded traffic for Predictive Oncology is 270 monthly website visits, down 38.6% over the last three months. Predictive Oncology's team declined 11.3% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
Birchmere Ventures
Draper Triangle Ventures
TVM Capital Life Science
Series B and later10 investors entered at this stage
Adams Capital Management
Boldcap Ventures
Stephens
Techno Venture Management
Quaker Bio Ventures
Longitude Capital
Bain Capital
Bain Capital Ventures
HealthCare Royalty
Skyline Medical Inc.
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Predictive Oncology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Predictive Oncology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.